Before industry trade groups can start negotiating with FDA on reauthorization of the biosimilar user fee program in earnest, they may first have to compromise on a common set of changes amongst themselves.
As part of the first negotiating session, the industry representatives present, which included four representatives from the Pharmaceutical Research and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?